Membranous Glomerulonephritis: Practice Essentials, Pathophysiology, Epidemiology (original) (raw)

Overview

Practice Essentials

Membranous nephropathy (MGN) is the most common cause of nephrotic syndrome in the adult population, but also occurs in children. [1] Approximately 80% of MGN cases are idiopathic; the remainder are secondary (eg, to malignancy, infectious disease, or an autoimmune disorder). Idiopathic and secondary MGN can be distinguished by clinical, laboratory, and histological features (see Presentation and Workup).

In secondary MGN, successful treatment of the underlying cause may be curative. Patients with idiopathic MGN may experience spontaneous remission, persistent proteinuria of variable degree, or progression to kidney failure. Immunosuppressive therapy may be appropriate for selected patients with idiopathic MGN who are at elevated risk for kidney dysfunction (see Treatment and Medication). [2]

Pathophysiology

Membranous nephropathy is an autoimmune disorder in which immune complexes deposit along the subepithelial region of the glomerular basement membrane. Antigen-antibody complexes can develop by the production of immune complexes in situ or by deposition of circulating complexes. In the Heymann nephritis model of experimental membranous nephropathy in rats, the intrinsic antigen is a glycoprotein, megalin, synthesized by the glomerular visceral epithelial cells; however, megalin is not present in the human glomerulus. [3]

M-type phospholipase A2 receptor (PLA2R) has been identified as the major target antigen in idiopathic membranous nephropathy in adults. Circulating autoantibodies against PLA2R have been found in 70-80% of patients with idiopathic membranous nephropathy. [4, 5] Anti-PLA2R antibodies are typically not found in patients with secondary membranous nephropathy. [4] Anti-PLA2R antibodies have been found in patients with viral infections (eg, hepatitis B, hepatitis C, HIV), but those patients may have had coincidental primary membranous nephropathy. [6] Detection of anti-PLA2R antibodies in glomeruli but not in liver parenchyma is a common finding in phatients with membranous nephropathy associated with autoimmune liver disease, suggesting that these autoantibodies are not exclusive to idiopathic membranous nephropathy. [7]

Another minor antigen is thrombospondin type 1 domain–containing 7A (THSD7A). Patients who are positive for anti-THSD7A autoantibodies represent a distinct subgroup with this disease and make up approximately 2.5 to 5% of adultts with idiopathic membranous nephropathy. [8, 9] Hoxha et al reported expression of THSD7A in a gallbladder carcinoma, in a patient who developed membranous nephropathy with anti-THSD7A antibodies, and subsequently found anti-THSD7A antibodies in six other patients with membranous nephropathy and malignant tumors, suggesting that THSD7A production by malignancies is a possible mechanism for membranous nephropathy. [10]

Other target antigens detected in patients with membranous nephropathy include the following [11] :

• Exostosin 1/exostosin 2 (EXT1/EXT2) - Predominantly present in women; most patients have an underlying autoimmune disease (eg, systemic lupus erythematosus, mixed connective tissue disease)
• Neural EGF-like-1 protein (NELL-1) - Associated with malignancy
• Semaphorin 3B (Sema3B) - Accounts for approximately 15% of pediatric membranous nephropathy cases but only 1-3% of adult cases
• Protocadherin 7 (PCDH7) - Occurs in children and young adults, some of whom have a positive family history

Debiec et al reported that four of nine patients with childhood membranous nephropathy had high levels of circulating anti–bovine serum albumin antibodies and circulating cationic bovine serum albumin. Bovine serum albumin was also seen in immune deposits. It is present in cow's milk and beef protein and can escape the intestinal barrier and cause antibody formation. Its cationic nature allows binding to the anionic glomerular capillary wall with resultant immune complex formation, a parallel to experimental models. This possible environmental trigger could lead to childhood membranous nephropathy, and improvement may be found by eliminating it from the diet. [12]

Neutral endopeptidase, a podocyte antigen that can digest biologically active peptides, was identified as the target antigen in a subset of patients with antenatal membranous nephropathy. In these cases, the patients' mothers carried a mutation that rendered them deficient in neutral endopeptidase and they had undergone alloimmunization due to exposure to paternal neutral endopeptidase during pregnancy. [13]

Many of the antigens associated with secondary membranous nephropathy are also not known. However, hepatitis B surface antigens and hepatitis E antigens have been identified in immune deposits, as have thyroid antigens in patients with thyroiditis.

The complement membrane attack complex (C5b-9) triggers the biosynthesis of oxygen radical–producing enzymes within the glomerular epithelial cells. The finding of urinary C5b-9 has been suggested as a diagnostic test for following disease activity. [14]

C5b-9 in sublytic quantities stimulates podocytes to produce proteases, oxidants, prostanoids, extracellular matrix components, and cytokines, including transforming growth factor-beta (TGF-beta). C5b-9 also causes alterations of the cytoskeleton that lead to an abnormal distribution of slit diaphragm protein and detachment of viable podocytes that are shed into the Bowman space. These events result in disruption of the functional integrity of the glomerular basement membrane and the protein filtration barrier of podocytes with subsequent development of massive proteinuria.

A study by Kuroki et al found that the immune response in idiopathic membranous nephropathy is characterized by alteration of T-cell function to produce Th2 cytokines and increased production of IgG4 by B cells in response to those cytokines. [15] A study by Cohen et al pointed to the involvement of B cells in the pathogenesis of membranous nephropathy, possibly as antigen-presenting cells. These authors measured the interstitial expression of CD20 messenger RNA (mRNA) in patients with membranous nephropathy and in control subjects with other kidney diseases. CD20 mRNA expression was significantly higher in patients with membranous nephropathy than in control subjects. B-cell infiltration was confirmed by immunohistochemistry. [16]

Epidemiology

Frequency

United States

The annual incidence of membranous nephropathy in the United States is estimated at about 12 cases per million population. Membranous nephropathy accounts for approximately 1.9 cases of end-stage kidney disease (ESKD) per million population per year in the US; hence, because only 10-20% of patients with primary membranous nephropathy progress to ESKD, the actual incidence may be as high as 20 cases per million population per year. [6]

Primary membranous nephropathy comprises about 80% of cases, while the remainder are secondary to other systemic diseases or exposures (eg, malignancy, infectious disease, autoimmune disorders). [6, 11, 13] The relative distribution of pathologic causes of nephrotic syndrome varies considerably among various centers, based on population and referral pattern factors.

In the pediatric population, membranous nephropathy is rare but serious. Membranous nephropathy is found in 1-7% of kidney biopsies in children. [6] Long-term prognosis is guarded because approximately 50% of patients may have evidence of progressive kidney disease. [17]

International

Internationally, the frequency is the same as in the United States, although it is influenced by the prevalence of secondary causes. These include infectious disease such as malaria in Africa and hepatitis B in parts of Asia. [18]

Mortality/Morbidity

The course is variable, and patients may be divided into 3 groups of approximately equal size (ie, "rule of thirds").

• Spontaneous complete remission - Kidney function is normal, with or without subsequent relapse.
• Persistent proteinuria of variable degree - Kidney function is normal or impaired but stable.
• Progressive disease, eventually leading to ESKD) - The incidence rate of ESRD is 14% at 5 years, 35% at 10 years, and 41% at 15 years.

Patients in the first and second category die from nonrenal causes.

Race-, sex-, and age-related demographics

Epidemiologic features include the following [13, 18, 6] :

• Race: In nondiabetic white adults, membranous nephropathy is the most common cause of idiopathic nephrotic syndrome. In some nondiabetic ethnic populations (eg, Blacks, Hispanics), however, membranous nephropathy is less common than focal segmental glomerulosclerosis.
• Sex: Membranous nephropathy has a predilection for males over females, with a male-to-female ratio of 2:1.
• Age: Mean age of onset is from 50 to 60 years. Onset outside the usual range is more likely to be a result of secondary causes.

Prognosis

Overall, patients with primary membranous nephropathy have a good prognosis. Approximately 30% of patients undergo spontaneous remission and another 30% have variable degrees of proteinuria but stable kidney function for many years. However, about 30% progress to kidney failure. Factors at presentation that have been associated with a poor prognosis include male gender, older age, high levels of proteinuria, and abnormal kidney function. [18]

Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using clinical and laboratory criteria for assessing risk of progressive loss of kidney function in patients with membranous nephropathy. On the basis of those criteria, patients can be classified into one of four risk groups (low, moderate, high, or very high), which serves as a guide for therapy. [19]

Criteria for low risk are as follows:

• Normal estimated glomerular filtration rate (eGFR) and proteinuria < 3.5 g/d and serum albumin > 30 g/L or
• Normal eGFR, proteinuria < 3.5 g/d or decreased > 50% after 6 consecutive months of conservative therapy with an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB)

Criteria for moderate risk are as follows:

• Normal eGFR
• Proteinuria > 3.5 g/d and not decreased > 50% after 6 consecutive months of conservative ACEi/ARB therapy
• Not fulfilling high-risk criteria

Criteria for high risk are as follows:

• eGFR < 60 mL/min/1.73 m2 and/or proteinuria > 8 g/d for > 6 months or
• Normal eGFR, proteinuria > 3.5 g/d and not decreased > 50% after 6 consecutive months of conservative ACEi/ARB therapy and at least one of the following:
• Serum albumin < 25 g/L
• Anti-PLA2R antibodies > 50 RU/mL
• Urinary alpha-1 microglobulin > 40 μg/min
• Urinary IgG > 1 μg/min
• Urinary beta-2 microglobulin > 250 mg/d
• Selectivity index > 0.20 (calculated as clearance of IgG/clearance of albumin)

Criteria for very high risk are as follows:

• Life-threatening nephrotic syndrome or
• Rapid deterioration of kidney function not otherwise explained

1. Ronco P, Beck L, Debiec H, Fervenza FC, Hou FF, Jha V, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021 Sep 30. 7 (1):69. [QxMD MEDLINE Link].
2. Tran TH, J Hughes G, Greenfeld C, Pham JT. Overview of current and alternative therapies for idiopathic membranous nephropathy. Pharmacotherapy. 2015 Apr. 35 (4):396-411. [QxMD MEDLINE Link].
3. Ronco P, Debiec H. Target antigens and nephritogenic antibodies in membranous nephropathy: of rats and men. Semin Immunopathol. 2007 Nov. 29 (4):445-58. [QxMD MEDLINE Link].
4. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009 Jul 2. 361(1):11-21. [QxMD MEDLINE Link]. [Full Text].
5. Reinhard L, Zahner G, Menzel S, Koch-Nolte F, Stahl RAK, Hoxha E. Clinical Relevance of Domain-Specific Phospholipase A2 Receptor 1 Antibody Levels in Patients with Membranous Nephropathy. J Am Soc Nephrol. 2020 Jan. 31 (1):197-207. [QxMD MEDLINE Link]. [Full Text].
6. Couser WG. Primary Membranous Nephropathy. Clin J Am Soc Nephrol. 2017 Jun 7. 12 (6):983-997. [QxMD MEDLINE Link]. [Full Text].
7. Dauvergne M, Moktefi A, Rabant M, et al. Membranous Nephropathy Associated With Immunological Disorder-Related Liver Disease: A Retrospective Study of 10 Cases. Medicine (Baltimore). 2015 Jul. 94 (30):e1243. [QxMD MEDLINE Link]. [Full Text].
8. Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med. 2014 Dec 11. 371 (24):2277-87. [QxMD MEDLINE Link]. [Full Text].
9. Iwakura T, Ohashi N, Kato A, Baba S, Yasuda H. Prevalence of Enhanced Granular Expression of Thrombospondin Type-1 Domain-Containing 7A in the Glomeruli of Japanese Patients with Idiopathic Membranous Nephropathy. PLoS One. 2015. 10 (9):e0138841. [QxMD MEDLINE Link]. [Full Text].
10. Hoxha E, Wiech T, Stahl PR, Zahner G, Tomas NM, Meyer-Schwesinger C, et al. A Mechanism for Cancer-Associated Membranous Nephropathy. N Engl J Med. 2016 May 19. 374 (20):1995-6. [QxMD MEDLINE Link]. [Full Text].
11. Sethi S. New 'Antigens' in Membranous Nephropathy. J Am Soc Nephrol. 2021 Feb. 32 (2):268-278. [QxMD MEDLINE Link]. [Full Text].
12. Debiec H, Lefeu F, Kemper MJ, Niaudet P, Deschênes G, Remuzzi G, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med. 2011 Jun 2. 364(22):2101-10. [QxMD MEDLINE Link].
13. Ronco P, Debiec H. Membranous nephropathy: A fairy tale for immunopathologists, nephrologists and patients. Mol Immunol. 2015 Nov. 68 (1):57-62. [QxMD MEDLINE Link]. [Full Text].
14. Coupes B, Brenchley PE, Short CD, et al. Clinical aspects of C3dg and C5b-9 in human membranous nephropathy. Nephrol Dial Transplant. 1992. 7 Suppl 1:32-4. [QxMD MEDLINE Link].
15. Kuroki A, Iyoda M, Shibata T, et al. Th2 cytokines increase and stimulate B cells to produce IgG4 in idiopathic membranous nephropathy. Kidney Int. 2005 Jul. 68(1):302-10. [QxMD MEDLINE Link].
16. Cohen CD, Calvaresi N, Armelloni S, Schmid H, Henger A, Ott U, et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol. 2005 May-Jun. 18 (3):328-33. [QxMD MEDLINE Link].
17. Chen A, Frank R, Vento S, et al. Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC Nephrol. 2007 Aug 6. 8:11. [QxMD MEDLINE Link].
18. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int. 2001 May. 59 (5):1983-94. [QxMD MEDLINE Link]. [Full Text].
19. [Guideline] Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct. 100 (4S):S1-S276. [QxMD MEDLINE Link]. [Full Text].
20. El Kossi M, Harmer A, Goodwin J, et al. De novo membranous nephropathy associated with donor-specific alloantibody. Clin Transplant. 2008 Jan-Feb. 22(1):124-7. [QxMD MEDLINE Link].
21. Alsharhan L, Beck LH Jr. Membranous Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021 Mar. 77 (3):440-453. [QxMD MEDLINE Link].
22. Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet. 2015 May 16. 385 (9981):1983-92. [QxMD MEDLINE Link].
23. Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol. 2014 Jun. 25 (6):1357-66. [QxMD MEDLINE Link]. [Full Text].
24. Chuang TW, Hung CH, Huang SC, et al. Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy. J Formos Med Assoc. 2007 Oct. 106(10):869-73. [QxMD MEDLINE Link].
25. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int. 1995 Jan. 47(1):225-30. [QxMD MEDLINE Link].
26. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Hladunewich M, et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012 Jan. 7(1):43-51. [QxMD MEDLINE Link]. [Full Text].
27. Chen Y, Schieppati A, Chen X, Cai G, Zamora J, Giuliano GA, et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2014 Oct 16. CD004293. [QxMD MEDLINE Link].
28. Gauckler P, et al; RITERM study group. Rituximab in Membranous Nephropathy. Kidney Int Rep. 2021 Apr. 6 (4):881-893. [QxMD MEDLINE Link]. [Full Text].
29. Fervenza FC, et al; MENTOR Investigators. Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy. N Engl J Med. 2019 Jul 4. 381 (1):36-46. [QxMD MEDLINE Link]. [Full Text].
30. Cravedi P, Ruggenenti P, Sghirlanzoni MC, et al. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol. 2007 Sep. 2(5):932-7. [QxMD MEDLINE Link].
31. Troyanov S, Roasio L, Pandes M, et al. Renal pathology in idiopathic membranous nephropathy: a new perspective. Kidney Int. 2006 May. 69(9):1641-8. [QxMD MEDLINE Link].

Author

Abeera Mansur, MD Consultant Nephrologist, Doctors Hospital and Medical Center, Pakistan; Nephrologist, CHI Health Good Samaritan of Kearney, Nebraska

Abeera Mansur, MD is a member of the following medical societies: American College of Physicians, American Society of Nephrology

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ajay K Singh, MB, MRCP, MBA Associate Professor of Medicine, Harvard Medical School; Director of Dialysis, Renal Division, Brigham and Women's Hospital; Director, Brigham/Falkner Dialysis Unit, Faulkner Hospital

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FASN Professor of Medicine, Section of Nephrology-Hypertension, Deming Department of Medicine, Tulane University School of Medicine

Vecihi Batuman, MD, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

James H Sondheimer, MD, FACP, FASN Professor of Medicine, Nephrology and Hypertension, Department of Medicine, Wayne State University School of Medicine; Medical Director, DaVita Kresge Dialysis (Detroit)

James H Sondheimer, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Nephrology

Disclosure: Nothing to disclose.